✦ LIBER ✦
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
✍ Scribed by Advani, R. H.; Buggy, J. J.; Sharman, J. P.; Smith, S. M.; Boyd, T. E.; Grant, B.; Kolibaba, K. S.; Furman, R. R.; Rodriguez, S.; Chang, B. Y.; Sukbuntherng, J.; Izumi, R.; Hamdy, A.; Hedrick, E.; Fowler, N. H.
- Book ID
- 115529365
- Publisher
- American Society of Clinical Oncology
- Year
- 2013
- Tongue
- English
- Weight
- 353 KB
- Volume
- 31
- Category
- Article
- ISSN
- 0732-183X
No coin nor oath required. For personal study only.